title: The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme.
abstract: The broad spectrum antiviral nucleoside ribavirin displays activity against a variety of RNA and DNA viruses. A number of possible mechanisms have been proposed during the past 30 years to account for the antiviral activity of ribavirin, including the possibility that ribavirin might have a negative effect on the synthesis of the RNA cap structure of viral RNA transcripts. In the present study, we investigated the possibility that ribavirin can directly serve as a substrate for the vaccinia virus RNA capping enzyme. We demonstrate that ribavirin triphosphate can be used as a substrate by the capping enzyme and can form a covalent ribavirin monophosphate-enzyme intermediate reminiscent of the classical GMP-enzyme intermediate. Furthermore, our data indicate that ribavirin monophosphate can be transferred to the diphosphate end of an RNA transcript to form the unusual RpppN structure. Finally, we provide evidence that RNA transcripts that possess ribavirin as the blocking nucleoside are more stable than unblocked transcripts. However, in vitro translation assays indicate that RNA transcripts blocked with ribavirin are not translated efficiently. Our study provides the first biochemical evidences that ribavirin can directly interact with a viral capping enzyme. The ability of a purified RNA capping enzyme to utilize ribavirin as a substrate has not been previously documented and has implications for our understanding of the catalytic mechanisms of RNA capping enzymes. The biological implications of these findings for the proposed ribavirin-mediated inhibition of capping are discussed.
authors.affiliation: Département de Biochimie, Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bougie
authors.forename: Martin
authors.initials: M
authors.lastname: Bisaillon
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D006152:Cyclic GMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D008780:Methyltransferases / Q000737:chemistry / Q000378:metabolism*; D008956:Models, Chemical; D009097:Multienzyme Complexes / Q000737:chemistry / Q000378:metabolism*; D009713:Nucleotidyltransferases / Q000737:chemistry / Q000378:metabolism*; D010744:Phosphoric Monoester Hydrolases / Q000737:chemistry / Q000378:metabolism*; D010957:Plasmids / Q000378:metabolism; D014176:Protein Biosynthesis; D012313:RNA / Q000737:chemistry; D012333:RNA, Messenger / Q000378:metabolism; D012254:Ribavirin / Q000494:pharmacology*; D013379:Substrate Specificity; D013997:Time Factors; D014616:Vaccinia virus / Q000201:enzymology; D014764:Viral Proteins; D000098556:mRNA Guanylyltransferases
chemical_list: D000998:Antiviral Agents; D009097:Multienzyme Complexes; D012333:RNA, Messenger; D014764:Viral Proteins; D012254:Ribavirin; D012313:RNA; D008780:Methyltransferases; D009713:Nucleotidyltransferases; D000098556:mRNA Guanylyltransferases; D010744:Phosphoric Monoester Hydrolases; C027731:capping enzyme, vaccinia virus; D006152:Cyclic GMP